Table 4.
Study | Beloosesky et al,12 n (%) | Dedovic et al,17,a n (%) | Gregory et al,18,b n (%) | Ishimaru et al,13 n (%) | Jain et al,14 n (%) | Ooi et al,15,c n (%) | Shabat et al,16 n (%) | |
---|---|---|---|---|---|---|---|---|
Dementia | NOM | 38 (48.8)d | 3 (13.6) | 10 (50.0) | 22 (35.5) | 46 (54.8)d | 15 (65.2)d | |
OM | 247 (38.2) | 28 (25.9) | ||||||
Ischemic heart disease/chronic heart failure | NOM | 67 (85.9)d | 31 (96.9) | 11 (50.0) | 12 (60.0) | 19 (30.6) | 8 (34.8)d | |
OM | 31 (91.2) | 158 (24.5) | 44 (40.7) | |||||
CVA/TIA | NOM | 12 (37.5) | 6 (27.3) | 6 (30.0) | 8 (12.9) | |||
OM | 16 (47.1) | 91 (14.1) | 24 (22.2) | |||||
Diabetes mellitus | NOM | 20 (25.6)d | 20 (62.5) | 6 (27.3) | 3 (15.0) | 5 (8.1) | 10 (43.5)d | |
OM | 22 (64.7) | 86 (13.3) | 14 (13.0) | |||||
COPD/asthma | NOM | 16 (20.5)d | 3 (13.6) | 3 (15.0) | 15 (24.2) | |||
OM | 44 (6.8) | 32 (29.6) | ||||||
Renal insufficiency | NOM | 11 (14.1)d | 6 (18.8) | 5 (25.0) | 7 (11.3) | |||
OM | 1 (2.9) | 31 (4.8) | 9 (8.3) | |||||
Malignancy | NOM | 5 (6.4)d | 4 (18.2) | 4 (20.0) | 14 (22.6) | |||
OM | 60 (9.3) | 9 (8.3) | ||||||
ASA score I/II | NOM | 33 (51.6) | 1 (4.5) | 2 (10.0) | 3 (4.8) | 62 (73.8)d | ||
OM | 13 (92.9) | 30 (37.5) | 385 (59.6) | 4 (3.7) | ||||
ASA score III/IV | NOM | 31 (48.4) | 21 (95.5) | 18 (90.0) | 59 (95.2) | 22 (26.2)d | ||
OM | 1 (7.1) | 50 (62.5) | 261 (40.4) | 104 (96.3) |
Abbreviations: ASA, American Society of Anesthesiologists; COPD, Chronic obstructive pulmonary disease; CVA, cerebrovacuscular accident; N, number of patients; NOM, nonoperative management; OM, operative management; TIA, Transient Ischaemic Attack.
aOnly inclusion of patients with 3 or more cardiac comorbid risk factors: chronic heart failure, previous myocardial infarction or angina pectoris, insulin-dependent diabetes mellitus, previous cerebrovascular insult or transitory ischemic attack, and renal insufficiency.
bOnly report for 22 nonoperatively treated patients.
cOnly report about dementia.
dTotal reported numbers for NOM and OM.